Advanced oral therapies for colorectal cancer via nanomedicine and microbiota modulation
Advanced Drug Delivery Reviews · 2026-01 · 228 · 115741
DOI: 10.1016/j.addr.2025.115741 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Drug Delivery Reviews, 2026-01. Verfasst von Yu Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Nanomedicine, Gastrointestinal Microbiome, Antineoplastic Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 277 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Sichuan University.
Abstract (Originalsprache)
Colorectal cancer (CRC) is the third most common malignancy and the second most lethal cancer worldwide and has become a significant burden on global healthcare. The primary treatments for CRC include surgery, chemotherapy, and targeted therapy. However, these approaches face several limitations, such as invasive administration, poor patient compliance, systemic toxicity, drug resistance, and recurrence. Thus, alternative therapeutic strategies to overcome these challenges are urgently needed. Oral administration represents a promising approach for CRC treatment because of its noninvasive nature, safety, ease of self-administration, and high patient compliance. Moreover, when applied in CRC treatment, oral therapies can potentially increase therapeutic efficacy and reduce systemic toxicity via local treatment. Furthermore, the unique pathophysiological features of CRC, such as the overexpression of certain receptors and dysbiosis, present valuable opportunities for the development of advanced oral therapies. This review focuses on cutting-edge oral therapies for CRC, including nanomedicine-based and bacteria-modulating strategies. These approaches show significant promise for improving therapeutic outcomes and can be combined with existing treatment modalities to improve efficacy and minimize adverse effects. Additionally, we provide critical perspectives on the challenges and future perspectives of these strategies for CRC management. This review aims to provide novel insights into the design and advancement of oral therapies, paving the way for more effective and patient-friendly CRC treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
- UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium.
- UCLouvain, Université catholique de Louvain, Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, 1200 Brussels, Belgium; WEL Research Institute, avenue Pasteur, 6, 1300 Wavre, Belgium. Electronic a…
- Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: yiningxu@scu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
- Sichuan University
- China Scholarship Council
- Fonds De La Recherche Scientifique - FNRS
- Science and Technology Department of Sichuan Province
Zitieren
APA
Wang, Y., Chen, C., Xiao, X., Kang, Y., He, J., Beloqui, A., & Xu, Y. (2026). Advanced oral therapies for colorectal cancer via nanomedicine and microbiota modulation. Advanced Drug Delivery Reviews, 228, 115741. https://doi.org/10.1016/j.addr.2025.115741
Vancouver
Wang Y, Chen C, Xiao X, Kang Y, He J, Beloqui A, et al. Advanced oral therapies for colorectal cancer via nanomedicine and microbiota modulation. Advanced Drug Delivery Reviews. 2026;228:115741. doi:10.1016/j.addr.2025.115741
BibTeX
@article{Wang2026,
author = {Wang, Yu and Chen, Cheng and Xiao, Xin and Kang, Yajing and He, Jinhan and Beloqui, Ana and Xu, Yining},
title = {Advanced oral therapies for colorectal cancer via nanomedicine and microbiota modulation},
journal = {Advanced Drug Delivery Reviews},
year = {2026},
volume = {228},
pages = {115741},
doi = {10.1016/j.addr.2025.115741}
}
EUVIMED